JW Pharmaceutical Corporation (KRX:001060)

South Korea · Delayed Price · Currency is KRW

26,025

+325 (1.26%)

Last updated: Aug 11, 2026, 11:54 AM KST

JW Pharmaceutical Financials Overview

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	789,947	775,298	719,376	748,527	684,351	606,585
Revenue Growth	9.11%	7.77%	-3.89%	9.38%	12.82%	10.82%
Gross Profit	373,591	359,314	323,498	335,542	287,955	234,376
Operating Income	99,447	87,877	82,733	96,631	60,490	30,848
Net Income	68,829	60,648	65,040	37,006	31,892	-967.85
Earnings Per Share	3103.24	2676.46	2644.00	1554.67	1373.14	-41.70
EPS Growth	21.69%	1.23%	70.07%	13.22%	-	-

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	66,319	61,341	32,551	94,196	149,678	65,666
Total Debt	54,125	54,635	91,726	170,280	209,542	245,145
Net Cash (Debt)	12,194	6,706	-59,175	-76,084	-59,864	-179,479
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	549.79	295.95	-2405.58	-3196.37	-2577.51	-7733.47

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	85,316	96,396	79,392	87,157	56,764	18,124
Capital Expenditures	-10,731	-11,772	-8,313	-27,286	-9,919	-7,467
Free Cash Flow	74,585	84,625	71,079	59,871	46,845	10,657
Free Cash Flow Growth	20.55%	19.06%	18.72%	27.81%	339.56%	-78.97%

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	47.29%	46.34%	44.97%	44.83%	42.08%	38.64%
Operating Margin	12.59%	11.34%	11.50%	12.91%	8.84%	5.08%
Pretax Margin	12.81%	11.46%	11.46%	7.33%	6.63%	3.38%
Profit Margin	8.71%	7.82%	9.04%	4.94%	4.66%	-0.16%
FCF Margin	9.44%	10.91%	9.88%	8.00%	6.84%	1.76%

Dividends

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 11, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Dividend Per Share	650.000	-	-	-	-	-
Dividend Per Share Growth	0%	-	-	-	-	-
Dividend Yield	2.67%	-	-	-	-	-

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 11, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PE Ratio	8.28	9.65	8.64	22.39	13.16	-
Forward PE	-	6.18	6.50	14.34	10.40	26.79
P/FCF Ratio	7.87	6.91	7.90	13.84	8.96	47.45
PS Ratio	0.74	0.75	0.78	1.11	0.61	0.83